ArticleACS omega2025
Boron Oxide Nanoparticles Exhibiting Defect-Activated Photoluminescence.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engineering emissive defects is key to developing fluorescent or phosphorescent compounds for optics and sensing applications in boron-based materials. The present work reports a bottom-up synthesis of boron oxide nanoparticles directly obtained from crystalline boron. The method does not employ organic solvents or harmful reactants and allows one to obtain pure boron oxide nanoparticles, avoiding the uncontrolled presence of carbon or other contaminants. The nanoparticles are formed through a two-step protocol: ultrasonication in water of bulk boron powder, followed by thermal annealing treatment in air. The first step allows for the formation of nanoparticles containing nonstoichiometric oxo-hydroxy BOH compounds, while the second induces dehydration and further oxidation of the boron species. The annealing temperature controls the number of defects formed during dehydration, and the defects modulate the nanoparticle fluorescence. The defects mainly comprise nonbridging oxygen within trigonal BO
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.